# SEQUENCE SPECIFIC SYNTHETIC MRNA CLEAVING AGENTS

> **NIH NIH R41** · ISIS PHARMACEUTICALS, INC. · 1994 · $100,000

## Abstract

The objective of this research is to improve the efficacy of action of
antisense oligonucleotides by equipping them with RNA specific cleaving
agents.  Recently, a series of lanthanide complexes have been designed,
synthesized, and characterized by Janet Morrow and co-workers (SUNY) which
catalyze the hydrolysis of the phosphodiester bond of RNA, and are inert
to metal ion- dissociation in solution. Two of these metal complexes,
La(S-ThP)3+ and Eu(THED)3+, will be covalently attached to an antisense
oligonucleotide that targets the mutant Ha-ras transcript. The conjugates
will be tested for activity in solution and cell culture assays.
Improvement in activity resulting from the incorporation of this new
technology into the existing repertoire of antisense technologies will
encourage further development and potential commercialization of this new
class of compounds for the treatment of infectious and non-infectious
diseases.

## Key facts

- **NIH application ID:** 2190321
- **Project number:** 1R41GM051646-01
- **Recipient organization:** ISIS PHARMACEUTICALS, INC.
- **Principal Investigator:** BRENDA F BAKER
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1994
- **Award amount:** $100,000
- **Award type:** 1
- **Project period:** 1994-07-01 → 1995-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/2190321

## Citation

> US National Institutes of Health, RePORTER application 2190321, SEQUENCE SPECIFIC SYNTHETIC MRNA CLEAVING AGENTS (1R41GM051646-01). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/2190321. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*